Biotech: Page 3
-
Permission granted by Amylyx Pharmaceuticals
Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug
Where Amylyx ultimately failed in ALS, it could prevail in a rare disease. The doctor leading this research explains why.
By Meagan Parrish • April 19, 2024 -
Stock via Getty Images
Roivant spinoff tackles growing complexity of clinical trials
As precision medicine booms, all trials are starting to look like rare disease trials, the company said.
By Kelly Bilodeau • April 18, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Chris McGrath via Getty Images
Deep DiveUkraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?
New clinical trial starts are picking back up, but are still far below their bustling pre-war level.
By Meagan Parrish • April 16, 2024 -
Permission granted by Ocugen
Biotech SpotlightTraditional gene therapies are uber-niche. Ocugen hopes to change that.
The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.
By Alexandra Pecci • April 15, 2024 -
Stock via Getty Images
3 big recent trial flops
How these clinical setbacks impacted the companies, industry and patients.
By Meagan Parrish • April 12, 2024 -
Permission granted by eClinical Solutions
Q&AHow pharma’s surging M&A is impacting the industry’s tech sector
As dealmaking in biopharma picks up, the CEO of eClinical Solutions sees an opportunity for clinical software companies to make acquisitions easier to close.
By Michael Gibney • April 11, 2024 -
Permission granted by Bristol Myers Squibb
Deep DivePsychiatry drugs finally have pharma’s attention. Can they keep it?
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.
By Jacob Bell • April 10, 2024 -
Stock via Getty Images
Biotech SpotlightWhat’s old is new: The revival of a one-time radiotherapy cancer treatment
TAE Life Sciences is bringing radiation-based cancer therapy to clinical trials globally in the coming years.
By Amy Baxter • April 10, 2024 -
Getty Images via Getty Images
Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future
Biosimilars promise market competition for branded biologics, which in theory could drive down prices. But so far, winning market share has been a struggle.
By Michael Gibney • April 9, 2024 -
Stock via Getty Images
Viral return: 3 U.S. cases concerning experts
Infectious diseases that were “off the playing field” are now making a comeback.
By Meagan Parrish • April 5, 2024 -
Permission granted by Verastem
Q&A // First 90 DaysWith an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
By Michael Gibney • April 4, 2024 -
Stock via Getty Images
As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene
AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
By Amy Baxter • April 3, 2024 -
Getty Images via Getty Images
A dementia-focused VC digs past anti-amyloid for neuroscience diamonds in the rough
Even as new drugs like Eisai and Biogen’s Leqembi make a splash in Alzheimer’s, VCs like the Dementia Discovery Fund have invested in the next wave of therapies.
By Michael Gibney • April 2, 2024 -
Scott Olson/Staff via Getty Images
With a rise in animal-human organ transplants, a drugmaker aims for a new standard of care
Eledon Pharmaceuticals is developing a drug that could facilitate organ transplants from animals to humans as the procedure gains steam.
By Kelly Bilodeau • April 1, 2024 -
Permission granted by Rivus Pharmaceuticals
To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach
Rivus’ controlled metabolic accelerators are an emerging new potential competitor to popular weight loss and diabetes drugs from Novo Nordisk and Eli Lilly.
By Amy Baxter • March 29, 2024 -
Permission granted by Cardior
‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field
Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior CEO Claudia Ulbrich.
By Michael Gibney • March 28, 2024 -
Permission granted by Art Krieg
Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup
With Zola Therapeutics, Krieg plans to design and sell a series of cancer immunotherapies without the help of outside investors, he told BioPharma Dive.
By Ben Fidler • March 28, 2024 -
Permission granted by Alnylam
Alnylam turns to genealogy to find rare disease patients through family trees
A vastly underdiagnosed rare disease presents a challenge to Alnylam’s commercial team, but a family health road trip has patients talking about their hereditary risk.
By Michael Gibney • March 26, 2024 -
Permission granted by Portal Bio
Q&ASQZ, Portal founder Armon Sharei on starting over in biotech
After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.
By Gwendolyn Wu • March 26, 2024 -
iStock via Getty Images
Who’s getting left behind in the weight loss bonanza?
As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.
By Kelly Bilodeau • March 25, 2024 -
Permission granted by Wyss Institute
Q&AAn ocean of answers in a single cell — how proteomics can lead to better drugs
New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.
By Michael Gibney • March 21, 2024 -
iStock via Getty Images
Orchard sets out to sell world’s priciest gene therapy
Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market.
By Kristin Jensen • March 20, 2024 -
Courtesy of Madrigal
With historic MASH approval, Madrigal preps for launch and a public offering
After snagging the first approval for MASH, Madrigal Pharmaceuticals’ drug is primed to become a blockbuster.
By Amy Baxter • March 20, 2024 -
Stock via Getty Images
Q&A // Biotech SpotlightGSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.
Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.
By Alexandra Pecci • March 19, 2024 -
Getty Images via Getty Images
As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help
A rebound in M&A seems to be on the docket, but analysts are warning companies to be intentional about where they go with it.
By Michael Gibney • March 19, 2024
Previous
